Opium Addiction and Ischemic Stroke in Isfahan, Iran: A Case-Control Study

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background: The effect of opium addiction (OA) on cerebrovascular disease is controversial. The aim of this study was to clarify this relationship in Iranian patients with ischemic stroke. Methods: In a case-control study, 672 patients with ischemic stroke and 293 controls without a previous history of cerebrovascular or cardiovascular diseases were compared. OA as well as other risk factors such as diabetes mellitus (DM), hypertension (HTN), hyperlipidemia, tobacco smoking (TS) were compared between the 2 groups. Results: OA percentage, TS, TS amount (pack/year), HTN and DM history were significantly higher in the case group compared to controls ( p < 0.05). After regression analysis between risk factors, a significant difference remained between 2 groups with regards to HTN (OR 4.21, 95% CI 3.05–5.81, p < 0.001), TS (OR 2.33, 95% CI 1.51–3.59, p < 0.001), and OA (OR 2.36, 95% CI 1.16–4.85, p = 0.018). Conclusion: Our study showed OA is a risk factor for stroke. However, a follow-up study with a larger cohort is required to confirm the results.

Related collections

Author and article information

Journal

Journal ID (publisher-id): ENE

Journal ID (nlm-ta): Eur Neurol

Journal ID (doi): 10.1159/issn.0014-3022

Title: European Neurology

Publisher: S. Karger AG

ISSN (Print): 0014-3022

ISSN (Electronic): 1421-9913

Publication date Subscription-year: 2018

Publication date (Print): March 2018

Publication date (Electronic): 22 December 2017

Volume: 79

Issue: 1-2

Pages: 82-85

Affiliations

[_a] _aSchool of Medicine, Islamic Azad University, Najafabad Branch, Isfahan, Iran

[_b] _bDepartment of Physiology, Applied Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

[_c] _cDepartment of Tissue Engineering and Regenerative Medicine, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

[_d] _dSocial Health Determinants Research Center and Department of Epidemiology and Biostatistics, School of Health, Shahrekord University of Medical Sciences, Shahrekord, Iran

[_e] _eIsfahan Neurosciences Research Center, Alzahra Research Institute, Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran

Author notes

*Dr. Mohammad Saadatnia, Isfahan Neurosciences Research Center, Alzahra Hospital, Department of Neurology, Isfahan University of Medical Sciences, Isfahan 8174673461 (Iran), E-Mail mosaadatnia@yahoo.com

Article

Publisher ID: 485098 Other ID: Eur Neurol 2018;79:82–85

DOI: 10.1159/000485098

PubMed ID: 29275418

SO-VID: e00ecf7e-fff2-40e5-9b49-1cb929e4450e

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

History

Date received : 30 March 2017

Date accepted : 07 November 2017

Page count

Tables: 2, Pages: 4

Comments

Comment on this article

scite_

Cited by 8

See all cited by

Call for Papers: Sex and Gender in Neurodegenerative Diseases

Submit here before September 30, 2024